HomeToday’s HighlightsAmgen and UCB granted FDA approval of Evenity for osteoporosis in menopausal women at risk of bone fracture Amgen and UCB granted FDA approval of Evenity for osteoporosis in menopausal women at risk of bone fracture Today’s Highlights April 10, 2019 Amgen and UDB Granted FDA Approval of Evenity™ Amgen (AMGN) and UCB Pharmaceuticals (This content is for paid subscribers. Please click here to subscribe or here to log in. Today’s Highlights Amgen (AMGN), UCB Pharmaceuticals (UCB) April 10, 2019 Tweet Pin It Other Articles Gilead Therapeutics and Genesis Therapeutics Announced Strategic Collaboration to Discover and Develop Novel Therapies September 10, 2024 0 Gilead Sciences Livdelzi Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA August 15, 2024 0 Akero Therapeutics Reports Q2 2024 Financial Results and Business Update August 9, 2024 0 Lexeo Therapeutics Announces Positive Data of lx2006 for the Treatment of Friedreich Ataxia Cardiomyopathy July 16, 2024 0